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Satavaptan for the management of ascites in
cirrhosis: efficacy and safety across the spectrum of
ascites severity
Florence Wong,1 Hugh Watson,2 Alexander Gerbes,3 Hendrik Vilstrup,4
Salvatore Badalamenti,5 Mauro Bernardi,6 Pere Ginès,7 for the Satavaptan
Investigators Group
ABSTRACT
Objective Satavaptan, a vasopressin V2 receptor
antagonist, has been shown to improve the control of
ascites in cirrhosis in short-term phase II studies. The
aim of this study was to evaluate the efficacy and safety
of satavaptan in three different populations of patients
with cirrhosis and ascites.
Methods 1200 patients were included in three
randomised double-blind studies comparing satavaptan
with placebo in uncomplicated ascites (study 1: n¼463
patients) and difficult-to-treat ascites, with and without
concomitant diuretic treatment (studies 2 and 3: n¼497
and n¼240 patients, respectively).
Results Satavaptan was not more effective than placebo
in the control of ascites in any of the populations studied
as estimated by the primary efficacy endpoints: worsening
of ascites (study 1) and the cumulative number of large-
volume paracenteses during 12 weeks (studies 2 and 3).
Nevertheless, some of the secondary efficacy endpoints
related to the treatment of ascites were met in the three
studies, suggesting a slight advantage of satavaptan over
placebo in delaying ascites formation. Moreover,
satavaptan was more effective than placebo in improving
the serum sodium concentration in patients with
hyponatraemia. The incidence of major complications of
cirrhosis during follow-up did not differ significantly
between the satavaptan and placebo groups in the three
studies. Overall, the rate of any treatment-related adverse
events, serious treatment-related events and treatment-
related events leading to permanent discontinuation of
treatment did not differ significantly between the
treatment groups. However, in study 2 mortality was
higher in patients treated with satavaptan compared with
placebo (HR 1.47; 95% CI 1.01 to 2.15); no significant
differences in mortality between the two groups were
observed in the other two studies. No specific cause for
the increased mortality was identified. Most deaths were
associated with known complications of liver cirrhosis.
Conclusion Satavaptan, alone or in combination with
diuretics, is not clinically beneficial in the long-term
management of ascites in cirrhosis.
The management of ascites in patients with
cirrhosis can be difficult because patients either do
not respond to diuretics or they develop complica-
tions during treatment.1e4 In the last 40 years no
significant advances have been made in the phar-
macological therapy of ascites in cirrhosis. Recently,
a new family of drugs that increase urine volume
has been developed.5 These drugs, known as
vaptans, act by antagonising selectively the renal
vasopressin V2 receptors causing an increase in
solute-free water excretion and serum sodium
concentration.5 Some of these drugs have been
approved in several countries for the management
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Significance of this study
What is already known about this subject?
< The pharmacological management of ascites in
cirrhosis is unsatisfactory in some patients
because of a lack of response to treatment
with standard diuretics.
< Patients with cirrhosis and ascites generally
have increased secretion of vasopressin from
the neurohypophysis which participates in the
pathogenesis of fluid retention.
< Vaptans are a new family of orally active drugs
that increase urine volume by antagonising
specifically the vasopressin V2 receptors in the
principal cells of the collecting ducts that have
been shown to reduce ascites in phase II studies.
What are the new findings?
< The V2 vasopressin antagonist satavaptan is
more effective than placebo on a long-term
basis in increasing the serum sodium concen-
tration in patients with cirrhosis, ascites and
hyponatraemia.
< The V2 vasopressin antagonist satavaptan only
offers a marginal beneficial effect compared
with conventional treatment in the management
of ascites in cirrhosis.
How might it impact on clinical practice in the
foreseeable future?
< The combination of diuretics and vasopressin V2
antagonists does not seem to be an effective
approach for the long-term management of
ascites and oedema in cirrhosis.
< The use of vaptans in cirrhosis should be
restricted to the management of hypervolaemic
hyponatraemia. Appropriately designed long-
term studies assessing the efficacy and safety
of vaptans for this indication are needed.
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of hypervolaemic hyponatraemia in association with cirrhosis
and ascites, heart failure and syndrome of inappropriate anti-
diuretic hormone secretion.6 7 Short-term phase II studies with
the V2 receptor antagonist satavaptan in patients with cirrhosis
and ascites have shown that it decreases ascites volume and the
need for large-volume paracentesis (LVP).8e10 The current
studies were therefore designed to test whether long-term
satavaptan administration may improve ascites in cirrhosis. The
current report describes the results of three large randomised
double-blind comparative studies of satavaptan versus placebo in
three different populations of patients with cirrhosis and ascites.
METHODS
Patient population and design of studies
One thousand and two hundred patients with cirrhosis and
ascites were included in three multicentre randomised double-
blind studies comparing satavaptan with placebo. The studies
were performed between July 2006 and December 2008. They
were approved by the appropriate regulatory agencies and ethics
committees for each participating institution and registered on
a public website (http://www.ClinicalTrials.gov registration
numbers NCT00358878, NCT00359437 and NCT00366795). All
patients gave written informed consent to participation.
The target populations were different in the three studies (see
later) but the exclusion criteria were identical. Patients with
a history of variceal bleeding or bacterial peritonitis in the
previous 10 days or hepatic encephalopathy grade >1 at the time
of randomisation were excluded; however, these patients could
be included at a later date. Other main reasons for exclusion of
patients were serum creatinine >151 mmol/l (1.7 mg/dl), serum
potassium >5.5 mmol/l, serum sodium >143 mmol/l, serum
bilirubin >150 mmol/l, INR >3.0, platelets <30 000/mm3,
neutrophils <1000/mm3, shock or hepatocellular carcinoma
exceeding the Milan criteria. Concomitant administration of
potent or moderate inhibitors of the cytochrome P450 3A
pathway or drugs known to increase the risk of QT interval
prolongation was not permitted during the studies.
The dose regimen of satavaptan was based on previous phase
II studies8e10 and was the same for each study, commencing
with a dose of 5 mg/day on the day of randomisation and
maintaining this daily dose for the first 7 days, following which
the dose could be increased to 10 mg/day according to the
investigator ’s judgement based on efficacy and tolerability.
Subsequent adjustments of the dose to 5 mg/day or 10 mg/day
could be made at any time as considered necessary. Duration of
treatment was 52 weeks in all three studies. The exposure to the
study drug and the average dose of satavaptan given in each of
the three studies are shown in table 1 in the online supplement.
Patients were followed up at intervals of no more than
4 weeks. Assessments of clinical status including ascites and
adverse events were recorded at each visit. Blood samples were
taken for serum chemistry and haematology at each visit and
analysed at a central laboratory. ECGs were also performed at
each visit and analysed by a central reader. Patients in all studies
were followed up for safety for 52 weeks after randomisation,
even in the case of early treatment discontinuation, in order to
obtain accurate estimates of mortality.
Study 1: Satavaptan versus placebo in combination with diuretics in
the management of ascites not requiring LVP
The objective of this study was to evaluate the efficacy and
safety of satavaptan in addition to conventional treatment in
the management of ascites. Patients studied were those with
clinically evident ascites being treated with a sodium-restricted
diet with or without diuretics and no history of repeated LVP in
the previous 6 months.
The planned sample size was a minimum of 440 patients.
Patients were randomised in a 1:1 ratio to receive satavaptan or
placebo with stratification for serum sodium (< or $135 mmol/
l) and current diuretic regimen (none, potassium-sparing diuretic
alone or any other diuretic alone or combination). Patients
continued on their sodium-restricted diet (<88 mmol/day) and
current regimen of diuretic agents. The primary efficacy
endpoint was the worsening of ascites during the first 12 weeks
of the study, defined as LVP and/or weight increase of $2 kg
since the baseline measurement (including the weight of
any ascitic fluid removed by LVP) and/or premature study
discontinuation.
Other ascites endpoints evaluated were: (1) time to reduction
of ascites, defined as a decrease in body weight of $2 kg
compared with baseline without any LVP or increase in diuretic
regimen; (2) worsening of ascites during the first 24 weeks using
a threshold of 4 kg body weight increase from baseline; (3) time
to first LVP; (4) cumulative number of LVPs; and (5) cumulative
increase in ascites estimated by the addition of weight change
since randomisation and the weight of any ascitic fluid drained
by LVP.
Non-ascites endpoints evaluated included the risk of other
major complications of cirrhosis such as hepatic encephalopathy,
spontaneous bacterial peritonitis, variceal bleeding and renal
impairment (defined as serum creatinine increase over baseline
>50% to a level >133 mmol/l or 1.5 mg/dl). Time to correction
of hyponatraemia (>135 mmol/l) was also evaluated in patients
with a starting serum sodium level #130 mmol/l.
Study 2: Satavaptan versus placebo in combination with diuretics in
the prevention of recurrent ascites after LVP
The objective of this study was to evaluate the efficacy and
safety of satavaptan in addition to diuretics in the prevention of
recurrence of ascites in patients with a history of frequent LVP.
Patients studied were those with recurrent ascites having a LVP
of at least 4 litres less than 24 h before randomisation and with
a history of at least one other LVP in the previous 3 months. All
patients had to be receiving a sodium-restricted diet and one or
more diuretic agents.
The planned sample size was a minimum of 450 patients.
Patients were randomised in a 2:1 ratio to receive satavaptan or
placebo with stratification for diuretic regimen (as for study 1)
and for the interval between the two previous paracenteses (#
or >28 days). Patients continued on their sodium-restricted diet
and current regimen of diuretic agents.
The primary efficacy endpoint was the cumulative number of
LVPs (defined as the removal of at least 1 litre of ascites) during
the first 12 weeks of the study. Other ascites endpoints evalu-
ated were: (1) time to first LVP; (2) time to recurrence of ascites,
defined as LVP and/or weight increase of$4 kg since the baseline
measurement; and (3) cumulative increase in ascites estimated
by the addition of weight change since randomisation and the
weight of any ascitic fluid drained by LVP.
Non-ascites endpoints evaluated included the risk of other
major complications of cirrhosis (see study 1) and time to
correction of hyponatraemia.
Study 3: Satavaptan versus placebo as single therapy in the
prevention of recurrent ascites after LVP
The objective of this study was to evaluate the efficacy and
safety of satavaptan in the prevention of recurrence of ascites in
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patients with a history of frequent LVP not being treated with
diuretics because of refractory ascites.
Patients studied were those with recurrent ascites having
a LVP of at least 4 litres less than 24 h before randomisation and
a history of at least one other LVP in the previous 3 months.
Patients had to be receiving a sodium-restricted diet but were
unsuitable for treatment with diuretic agents and such drugs
were not to be administered during the first 12 weeks of the
study.
The planned sample size was a minimum of 225 patients.
Patients were randomised in a 2:1 ratio to receive satavaptan or
placebo with stratification for baseline serum sodium (as for
study 1) and the interval between the two previous LVPs (as for
study 2). Patients continued on their sodium-restricted diet. The
primary efficacy endpoint was the cumulative number of LVPs
(of at least 1 litre of ascites) during the first 12 weeks of the
study.
Other ascites endpoints evaluated were: (1) time to first LVP;
(2) time to recurrence of ascites, defined as LVP and/or weight
increase of $4 kg since the baseline measurement; and (3)
cumulative increase in ascites estimated by the addition of
weight change since randomisation and the weight of any ascitic
fluid drained by LVP.
Non-ascites endpoints evaluated included the risk of other
major complications of cirrhosis (see study 1) and time to
correction of hyponatraemia.
Statistical methods
The planned sample sizes were calculated based on data from
completed phase II studies8e10 to give studies sufficient power
to detect HRs of satavaptan versus placebo of 0.6 (study 1), 0.7
(study 2) and 0.7 (study 3) in the primary efficacy endpoint,
with a power of at least 90% at the 5% significance level.
Analysis methods were designed to take into account varia-
tions in duration of exposure and observation, as a high rate of
discontinuation could be expected in studies of patients with
end-stage liver disease. The intent-to-treat population (all
patients randomised and exposed to treatment) was used for
analysis. Cumulative numbers of events over time were analysed
using NelsoneAalen estimates and a Cox model for recurrent
events. Time to first event was analysed using KaplaneMeier
estimates and a Cox model. The rate of ascites accumulation
was estimated by comparing the slopes in a regression analysis
of the volume over time, taking into account the individual
weight change, total volume of ascites removed by LVP and
duration of observation. p Values <0.05 were considered statis-
tically significant. Primary efficacy analyses were adjusted for
the following baseline covariates: serum sodium, concomitant
diuretic regimen (studies 1 and 2), interval between the two
previous LVPs (studies 2 and 3) and geographical region.
RESULTS
Study 1: Satavaptan versus placebo in combination with
diuretics in the management of ascites in patients not requiring
LVP
The disposition of all the patients is shown in figure 1 in the
online supplement. The two treatment arms were well-matched
at baseline for demographic and disease characteristics (table 1).
The duration of exposure to study drug and the use of
concomitant diuretics was similar in the two treatment arms
(see tables 1 and 2 in online supplement).
There was no statistically significant effect in the first
12 weeks in the incidence of worsening ascites in the satavaptan
group compared with the placebo group, although there was
a tendency for a better control of ascites in the satavaptan group
(RR 0.85, 95% CI 0.67 to 1.09, p¼0.2034; figure 1). There was
also no statistically significant difference between the two
groups over 52 weeks of treatment. Similar results were
observed whether using the threshold of 2 kg or 4 kg to define
worsening of ascites.
The time to reduction of ascites was shorter in those receiving
satavaptan than in the placebo group (RR 1.48, 95% CI 1.12 to
1.94, p¼0.005), a difference which emerged during the first
2 weeks of treatment (see figure 2 in online supplement). Time
to first LVP (RR 0.75, 95% CI 0.49 to 1.46) and the cumulative
number of LVPs over 52 weeks (RR 0.79, 95% CI 0.52 to 1.20)
were not significantly improved by satavaptan. The mean
cumulative increase in estimated ascites was lower in the sata-
vaptan group but the difference was not statistically significant
(0.12 l/week for satavaptan vs 0.21 l/week for placebo, a ratio of
0.58, 95% CI 0.07 to 1.09).
In patients with significant hyponatraemia at study entry, the
median time to correction of hyponatraemia was 8 days on
satavaptan compared with 43 days for placebo (RR 2.91, 95% CI
1.47 to 5.75). The percentage of patients in the study with
a serum sodium level >145 mmol/l on at least one occasion was
15.2% in the satavaptan group and 9.6% in the placebo group.
Two patients on satavaptan and one patient on placebo had an
initial increase in serum sodium of $8 mmol/l in the 24 h
following the first dose of the study treatment. The maximum
increase in 1 day was 10 mmol/l. These changes were not
associated with any adverse clinical events.
The incidence of major complications of cirrhosis did not
differ significantly between the two treatment arms (see table 3
in online supplement). Tests for renal function (including serum
creatinine and estimated glomerular filtration rate using the
Table 1 Baseline characteristics of patients in study 1: satavaptan
versus placebo in combination with diuretics in the management of







Age, years 56.4 (9.2) 56.6 (10.2) 56.5 (9.7)
Sex
Men 168 (73.0%) 158 (68.1%) 326 (70.6%)
Women 62 (27.0%) 74 (31.9%) 136 (29.4%)
Aetiology of cirrhosis, n*
Alcoholism 151 (65.7%) 148 (63.8%) 299 (64.7%)
Hepatitis C 49 (21.3%) 61 (26.3%) 110 (23.8%)
Hepatitis B 20 (8.7%) 18 (7.8%) 38 (8.2%)
Others 39 (17.0%) 38 (16.4%) 77 (16.7%)
Child-Pugh score 8.0 (1.6) 7.9 (1.5) 7.9 (1.5)
Child-Pugh class C, n 45 (19.6%) 33 (14.2%) 78 (16.9%)
MELD score 13.1 (3.8) 12.8 (4.4) 13.0 (4.1)
MELD-Na score 14.6 (5.7) 14.2 (5.9) 14.4 (5.8)
Serum bilirubin, mmol/l 36 (29) 33 (26) 35 (27)
Serum creatinine, mmol/l 80 (22) 79 (23) 79 (22)
Serum sodium, mmol/l 137 (4.5) 137 (4.2) 137 (4.3)
Ascites grade, n
Mild 91 (39.6%) 85 (36.6%) 176 (38.1%)
Moderate 126 (54.8%) 127 (54.7%) 253 (54.8%)
Marked 13 (5.7%) 20 (8.6%) 33 (7.1%)
History of any paracentesis, n 96 (41.7%) 105 (45.3%) 201 (43.5%)
Time since last paracentesis, days 427 (912) 318 (494) 370 (725)
History of hepatic encephalopathy, n 55 (23.9%) 44 (19.0%) 99 (21.4%)
Values are mean (SD) or n (%).
*Some patients may have more than one aetiology of cirrhosis.
MELD, model for end-stage liver disease.
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modified diet in renal disease (MDRD) formula),11 liver func-
tion, other serum chemistry and haematological parameters and
ECGs did not show any differences between the treatment
groups. No significant differences in the effects on blood
pressure and heart rate were observed between the two groups
(see table 4 in online supplement).
Overall, the percentage of treatment-related adverse events
(84.9% for satavaptan vs 86.1% for placebo), serious treatment-
related events (47.4% vs 49.6%) and treatment-related events
leading to permanent discontinuation of treatment (24.1% vs
22.2%) were similar for the two treatment groups.
During the 52 weeks of follow-up, 20.3% of patients in the
satavaptan group and 17.4% of those in the placebo group died
(RR for all-cause mortality during or after treatment 1.18, 95%
CI 0.78 to 1.81; see figure 3 in online (supplement). The inci-
dence of treatment-related events with a fatal outcome was
higher in the satavaptan group than in the placebo group (12.5%
vs 6.1%) but did not reach statistical significance (RR 2.01, 95%
CI 1.06 to 3.80). Most deaths were associated with known
complications of cirrhosis (table 2).
Study 2: Satavaptan versus placebo in combination with
diuretics in the prevention of recurrent ascites after LVP
The disposition of all the patients is shown in figure 4 in the
online supplement. After completion of enrollment but before
the treatment of all patients had been completed, the Drug
Safety Monitoring Board recommended the early termination of
this study due to an increased mortality in the satavaptan group.
At that time, 64 patients (19.3%) in the satavaptan group and
33 patients (19.5%) in the placebo group were still receiving
treatment.
The two treatment arms were well-matched at baseline for
demographic and disease characteristics (table 3). The mean
duration of exposure to study treatment and concomitant
diuretic use were similar in the two groups (see tables 1 and 2 in
online supplement).
There was no statistically significant effect of satavaptan in
the first 12 weeks on the cumulative number of LVPs compared
with the placebo group (RR 0.89, 95% CI 0.76 to 1.05, p¼0.17;
figure 2). The mean volume of ascites removed per LVP was
6.6 litres in the satavaptan group and 6.9 litres in the placebo
group. There was also no statistical difference in the number of
LVPs over 52 weeks of treatment.
The time to first LVP (RR 0.79, 95% CI 0.63 to 0.98, p¼0.03)
and time to first recurrence of ascites (RR 0.74, 95% CI 0.60 to
0.90, p¼0.0032; figure 5 in online supplement) were both
increased by satavaptan compared with placebo (25 days vs
22 days and 14 days vs 11 days, respectively). The mean
estimated increase in ascites volume was lower in the sata-
vaptan group than in the placebo group (2.0 l/week vs 2.4 l/
week, respectively, a ratio of 0.83, 95% CI 0.69 to 0.96, p¼0.02).
In patients with significant hyponatraemia at study entry, the
median time to correction of hyponatraemia was 8 days for the
satavaptan group and 43 days for the placebo group (RR 1.97,
95% CI 1.97 to 3.34). The percentage of patients in the study
with a serum sodium level >145 mmol/l was higher in the
satavaptan group than in the placebo group (9.5% vs 3.6%). Six
patients on satavaptan compared with no patient on placebo
had an initial increase in serum sodium of$8 mmol/l in the 24 h
following the first dose of the study treatment. The maximum
increase was 10 mmol/l and these changes were not associated
with any adverse clinical events.
The incidence of other major complications of cirrhosis did
not differ significantly between the two treatment arms
(see table 5 in online supplement).
During follow-up, significant increases in transaminases and
serum bilirubin (threefold) were more frequent in the satavaptan
group than in the placebo group (alanine aminotransferase
11.6% vs 6.0%, aspartate transaminase 9.5% vs 3.0%, bilirubin
8.8% vs 4.8%). In contrast, comparison of renal function
tests (serum creatinine and MDRD), other serum chemistries
and haematological parameters, arterial pressure, heart rate
Figure 1 KaplaneMeier analysis of
time to worsening ascites in study 1:
satavaptan versus placebo in
combination with diuretics in the
management of ascites not requiring
large-volume paracentesis. Median time
to event: satavaptan 9.2 weeks,
placebo 7.4 weeks (RR 0.85, 95% CI
0.67 to 1.09).
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(see table 4 in online supplement) and ECGs did not show any
consistent differences between the treatment groups.
Overall, the percentage of patients with any treatment-related
adverse events (87.9% for satavaptan vs 86.7% for placebo),
serious treatment-related events (60.0% vs 54.8%) and treat-
ment-related events leading to permanent discontinuation of
treatment (33.6% vs 28.3%) did not differ significantly between
the two treatment groups. Among the various types of adverse
events reported, the incidence of gastrointestinal (GI) bleeding
events showed the most marked difference between the treat-
ment groups (upper GI bleeding 10.9% vs 6.0%; lower GI
bleeding 3.3% vs 1.8%). Renal events overall were also more
frequent in the satavaptan group (30.9% vs 24.7%) but, within
that category, major events such as renal failure (7.0% vs 9.0%)
and hepatorenal syndrome (7.0% vs 7.8%) were reported less
frequently compared with placebo. The frequency of hyper-
kalaemia was similar in the two groups (satavaptan 27.4%
vs placebo 30.1%).
During the 52 weeks of follow-up 29.4% of patients in the
satavaptan group and 21.7% in the placebo group died (RR for
all-cause mortality during or after treatment 1.47, 95% CI 1.01
to 2.15, p¼0.049; figure 3). The incidence of treatment-related
events with a fatal outcome was also higher in the satavaptan
group than in the placebo group (14.8% vs 8.4%; RR 1.82, 95%
CI 1.00 to 3.29). Most deaths were associated with known
complications of liver cirrhosis (table 2).
Study 3: Satavaptan versus placebo as single therapy in the
prevention of recurrent ascites after LVP
The disposition of all the patients is shown in figure 6 in the
online supplement. After completion of enrollment but before
the treatment of all patients had been completed, the Drug
Safety Monitoring Board recommended the early termination of
this study due to poor risk-benefit. At that time, 21 patients
(13.0%) in the satavaptan group and 10 patients (12.5%) in the
placebo group were still receiving treatment.
The average duration of exposure to study treatment was
longer in the satavaptan group than in the placebo group
(median duration 152 days vs 76 days), mainly due to a higher
drop-out rate for lack of efficacy and patients leaving the study
for unspecified reasons in the placebo group.
Compared with patients in studies 1 and 2, patients in study 3
had more advanced liver disease and almost all had refractory
ascites (table 4).
There was no statistically significant effect in the first
12 weeks on the cumulative number of LVPs in the satavaptan
group compared with the placebo group (RR 0.90, 95% CI 0.74
to 1.09; figure 4), although there was a trend for better efficacy in
the satavaptan group. There was also no statistical significance
between the two groups over 52 weeks of treatment.
The time to first LVP (RR 0.72, 95% CI 0.53 to 0.98,
p¼0.0354) and time to first recurrence of ascites (RR 0.67, 95%
CI 0.50 to 0.89, p¼0.0063; figure 7 in online supplement) were
both increased by satavaptan compared with placebo. The mean
cumulative increase in ascites was estimated to be 3.5 l/week for
satavaptan and 3.6 l/week for placebo, a ratio of 0.97, 95% CI
0.78 to 1.15 (p¼0.7334).
In patients with significant hyponatraemia at study entry, the
median time to correction of hyponatraemia was 7 days in the
satavaptan group and 30 days in the placebo group (RR 2.26,
95% CI 1.22 to 4.17). The percentage of patients in the study
with a serum sodium level >145 mmol/l was higher in the
satavaptan group than in the placebo group (13.0% vs 5.1%).
Three patients in the satavaptan group compared with one
patient in the placebo group had an initial increase in serum
sodium of $8 mmol/l in the 24 h following the first dose of the
study treatment. The maximum increase was 12 mmol/l and
these changes were not associated with any adverse clinical
events. The incidence of other major complications of cirrhosis
Table 2 Causes of death in the three studies
Study 1 Placebo (n[230) Satavaptan (n[232)
Hepatic encephalopathy 5 (2.2%) 4 (1.7%)
Variceal bleeding 5 (2.2%) 3 (1.3%)
Bacterial infections 6 (2.6%) 12 (5.2%)
Renal impairment 2 (0.9%) 6 (2.6%)
Liver failure 10 (4.3%) 7 (3.0%)
Non-hepatic causes 12 (5.2%) 15 (6.5%)
Total deaths (all causes) 40 (17.4%) 47 (20.3%)
Study 2 Placebo (n[168) Satavaptan (n[328)
Hepatic encephalopathy 5 (3.0%) 8 (2.4%)
Variceal bleeding 1 (0.6%) 11 (3.3%)
Bacterial infections 11 (6.5%) 20 (6.1%)
Renal impairment 6 (3.6%) 15 (4.6%)
Liver failure 9 (5.4%) 16 (4.9%)
Non-hepatic causes 5 (3.0%) 31 (9.5%)*
Total deaths (all causes) 37 (22.3%) 101 (30.6%)
Study 3 Placebo (n[80) Satavaptan (n[160)
Hepatic encephalopathy 0 (0%) 8 (5.0%)
Variceal bleeding 2 (2.6%) 8 (5.0%)
Bacterial infections 7 (8.8%) 16 (10.0%)
Renal impairment 1 (1.3%) 8 (5.0%)
Liver failure 13 (16.3%) 11 (6.9%)
Non-hepatic causes 4 (5.0%) 4 (2.5%)
Total deaths (all causes) 27 (34.2%) 55 (34.2%)
*Non-hepatic causes of death in study 2 included hypovolaemia, thromboembolic disorders,
cardiac events, respiratory disorders, cancers and accidents (falls).
Table 3 Baseline characteristics of patients included in study 2:
satavaptan versus placebo in combination with diuretics in the







Age, years 57.0 (9.8) 58.9 (10.0) 58.3 (10.0)
Sex
Men 113 (67.3%) 237 (72.3%) 350 (70.6%)
Women 55 (32.7%) 91 (27.7%) 146 (29.4%)
Aetiology of cirrhosis, n*
Alcoholism 122 (72.6%) 251 (76.5%) 373 (75.2%)
Hepatitis B 17 (10.1%) 27 (8.2%) 44 (8.9%)
Hepatitis C 34 (20.2%) 53 (16.2%) 87 (17.5%)
Others 23 (13.7%) 38 (11.6%) 61 (12.3%)
Child-Pugh score 8.8 (1.4) 8.8 (1.5) 8.8 (1.5)
Child-Pugh class C, n 48 (28.6%) 100 (30.6%) 148 (29.9%)
MELD score 13.3 (3.9) 13.3 (3.8) 13.3 (3.8)
MELD-Na score 15.4 (6.2) 15.5 (6.3) 15.5 (6.2)
Serum bilirubin, mmol/l 35 (26) 36 (29) 36 (28)
Serum creatinine, mmol/l 83 (26) 85 (27) 85 (26)
Serum sodium, mmol/l 136 (4.5) 136 (4.4) 136 (4.4)
Refractory ascites, n 100 (59.5%) 206 (62.8%) 306 (61.7%)
Number of paracenteses in last year 7.6 (7.8) 7.5 (8.8) 7.5 (8.5)
Time since last paracentesis, days 24.4 (19.1) 25.2 (21.6) 24.9 (20.8)
Volume of ascites removed at baseline, l 6.3 (2.4) 6.3 (2.3) 6.3 (2.3)
History of hepatic encephalopathy, n 47 (28.0%) 82 (25.1%) 129 (26.1%)
Values are mean (SD) or n (%).
*Some patients may have more than one aetiology of cirrhosis.
MELD, model for end-stage liver disease.
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did not differ significantly between the two treatment arms (see
table 6 in online supplement).
During follow-up, significant increases in serum bilirubin
(threefold) were more frequent in the satavaptan group than in
the placebo group (KaplaneMeier 52-week estimates 17.6% vs
1.7%). However, the frequency of elevations of liver trans-
aminases did not differ. There was also a higher frequency of
modest increases (>30%) in serum creatinine with satavaptan
(KaplaneMeier 52-week estimates 69.1% vs 45.5%) but
no difference in the frequency of more marked increases.
Comparison of renal function tests (serum creatinine and
MDRD), other serum chemistries, haematological parameters
and arterial pressure and heart rate (see table 4 in the online
supplement) did not show any substantial differences between
the treatment groups, but ECG analysis showed that 10 patients
(6.3%) in the satavaptan group had a QTcF interval $500 ms
compared with no patients in the placebo group.
Overall, the percentage of patients with any treatment-related
adverse events (87.0% for satavaptan vs 87.3% for placebo),
serious treatment-related events (60.9% vs 58.2%) and
Figure 2 Cumulative number of large-
volume paracenteses in study 2:
satavaptan versus placebo in
combination with diuretics in the
prevention of recurrent ascites after
large-volume paracentesis (RR 0.89,
95% CI 0.76 to 1.05).
Figure 3 KaplaneMeier analysis of
all-cause mortality up to 52 weeks in
study 2: satavaptan versus placebo in
combination with diuretics in the
prevention of recurrent ascites after
large-volume paracentesis (RR 1.47,
95% CI 1.01 to 2.15, p¼0.049).
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treatment-related events leading to permanent discontinuation
of treatment (40.4% vs 35.4%) did not differ significantly
between the two treatment groups. Among the various types of
adverse events reported, there was no single type of event for
which the risk of occurrence was increased in the satavaptan
group when taking into account the difference in duration of
treatment and observation between the two groups.
During the 52 weeks of follow-up 34.2% of patients in the
satavaptan group and 34.2% in the placebo group died (RR for
all-cause mortality during or after treatment 0.95, 95% CI 0.60
to 1.51; figure 5). The risk of a treatment-related event with
a fatal outcome on satavaptan was 1.68 (95% CI 0.74 to 3.83).
Most deaths were associated with known complications of
cirrhosis (table 2).
DISCUSSION
Clinical research in patients with cirrhosis has focused recently
on the potential beneficial effects of vaptans in the management
of renal sodium and water retention.8e10 12e14 The rationale is
that plasma vasopressin levels are increased in advanced cirrhosis
and contribute to hypervolaemic hyponatraemia.1 15 16 A
number of studies have shown that vaptans improve serum
sodium in patients with hyponatraemia without significant side
effects except for thirst.5e10 12 However, the efficacy of vaptans
in the management of ascites has not been evaluated thor-
oughly. The results of the three studies reported here indicate
that satavaptan is of limited efficacy in the control of ascites
across the different groups of patients with ascites. This was the
reason for reporting the three studies together. The results of the
current study are in contrast with results of phase II studies
showing that satavaptan reduced ascites volume and the need
for paracentesis.8e10 None of the primary efficacy endpoints
showed significant differences compared with placebo, which
clearly indicates that satavaptan is not effective in the
management of ascites either alone or in combination with
diuretics. On the basis of these results, more research on the
potential use of vaptans in the management of ascites does not
seem to be justified. There were, however, statistically signifi-
cant differences in some secondary endpoints, suggesting a slight
advantage of satavaptan over placebo in delaying the accumu-
lation of ascites. For example, in patients with ascites not
requiring LVP (study 1), satavaptan was more effective than
placebo in the reduction of ascites volume but was not effective
Table 4 Baseline characteristics of patients included in study 3:
satavaptan versus placebo as single therapy in the prevention of







Age, years 56.2 (9.9) 56.4 (9.6) 56.3 (9.7)
Sex
Men 50 (62.5%) 108 (67.5%) 158 (65.8%)
Women 30 (37.5%) 52 (32.5%) 82 (34.2%)
Aetiology of cirrhosis, n*
Alcoholism 45 (56.3%) 102 (64.2%) 147 (61.5%)
Hepatitis B 5 (6.3%) 13 (8.2%) 18 (7.5%)
Hepatitis C 24 (30.0%) 32 (20.1%) 56 (23.4%)
Others 13 (16.2%) 29 (18.1%) 42 (17.5%)
Child-Pugh score 9.3 (1.7) 8.9 (1.6) 9.0 (1.6)
Child-Pugh class C, n 37 (46.3%) 50 (31.3%) 87 (36.3%)
MELD score 14.4 (4.6) 13.7 (4.3) 13.9 (4.4)
MELD-Na score 19.1 (9.4) 16.8 (7.4) 17.6 (8.2)
Serum bilirubin, mmol/l 43 (34) 35 (26) 38 (29)
Serum creatinine, mmol/l 84 (28) 84 (26) 84 (27)
Serum sodium, mmol/l 134 (6) 135 (5) 135 (6)
Refractory ascites, n 72 (90.0%) 149 (93.1%) 221 (92.1%)
Number of paracenteses in last year 7.9 (9.0) 8.2 (10.1) 8.1 (9.7)
Time since last paracentesis, days 27.1 (27.0) 26.5 (26.3) 26.7 (26.5)
Volume of ascites removed at baseline, l 6.0 (2.1) 6.1 (2.7) 6.1 (2.5)
History of hepatic encephalopathy, n 26 (32.5%) 52 (32.5%) 78 (32.5%)
Values are mean (SD) or n (%).
*Some patients may have more than one aetiology of cirrhosis.
MELD, model for end-stage liver disease.
Figure 4 Cumulative number of large-
volume paracenteses in study 3:
satavaptan versus placebo as single
therapy in the prevention of recurrent
ascites after large-volume paracentesis
(RR 0.90, 95% CI 0.74 to 1.09).
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overall in the prevention of ascites worsening, which was the
primary endpoint. Similarly, in patients with difficult-to-treat
ascites requiring frequent LVP (studies 2 and 3) there was
a slight but significant reduction in the reaccumulation of ascites
and time to first recurrence of ascites, but treatment with
satavaptan did not reduce the number of LVPs over a 12-week
period compared with placebo. The dose of satavaptan used in
the current studies was not fixed and was in the low range of the
doses used in phase II studies (5e10 mg/day vs 5e25 mg/day,
respectively). However, it seems unlikely that this could have
contributed to the lack of efficacy of the drug because, in the
only phase II study in which patients received satavaptan for
a period of time similar to that used in the current studies to
assess the primary endpoints (12 weeks), the 5 mg/day dose was
similarly effective to the 12.5 and 25 mg/day doses in the
prevention of ascites recurrence.10 In contrast to the lack of
efficacy in the management of ascites, satavaptan was more
effective than placebo in improving the serum sodium concen-
tration in patients with hyponatraemia in the three populations
studied.
Besides the lack of clinically significant benefit of the use of
satavaptan in the management of ascites, the results of one of
the studies (study 2) show an increased risk of death in patients
treated with satavaptan compared with placebo. Surprisingly,
this effect was not observed in the other two studies. The cause
of this increased risk of death is both uncertain and intriguing
and was not related to geographical variations in the risk of
dying. There are a number of possible explanations. First, the
increased mortality could be related to the intrinsic effect of the
drug in increasing solute-free water excretion with potentially
subsequent dehydration and/or hypernatraemia.5 However,
although the frequency of hypernatraemia during follow-up was
slightly higher with satavaptan that with placebo, this was not
associated with clinically relevant side effects and in all cases the
serum sodium concentration recovered after treatment was
temporarily stopped. Moreover, the number of patients treated
with satavaptan who had sharp increases in the serum sodium
concentration ($8 mmol/l) was very low and none of them
developed neurological complications. Second, it is possible that
satavaptan, in association with diuretics, by increasing urine
losses could result in hypovolaemia and subsequent renal failure.
Nonetheless, the frequency of renal failure, which is a fairly
common complication in patients with ascites, was similar in
the satavaptan and placebo groups across the three different
patient populations. Moreover, the results of these phase III
studies as well as those of phase II studies indicate that treat-
ment with satavaptan in association with diuretics does not
result in an impairment of circulatory function.6e8 A third
possible explanation is that satavaptan could, for some
unknown reason, increase the risk of complications of cirrhosis
leading to a higher mortality. Nevertheless, the frequency of
complications of cirrhosis was similar in the satavaptan and
placebo groups in study 2 and also in studies 1 and 3. In two of
the three studies there was a higher frequency of increased
serum transaminasses (study 2) and bilirubin (studies 2 and 3) in
patients in the satavaptan group compared with those in the
placebo group. Although there is no evidence for satavaptan-
induced liver injury in phase II studies or in long-term animal
toxicology studies, this possibility cannot be completely
excluded. Finally, we cannot rule out that the increased risk of
death observed in study 2 was due to a type 1 error. In fact,
differences in the risk of death between satavaptan and placebo
groups were only significant at 52 weeks and not in early periods
of follow-up (3 and 6 months), and the difference was only just
at the level of significance (p¼0.049). In this regard, it is also
important to note that 97 patients (64 in the satavaptan group
and 33 in the placebo group) had not finished the follow-up at
the time of study discontinuation. Moreover, the observation
that mortality in the satavaptan and placebo groups in the other
two populations of patients (studies 1 and 3) was almost iden-
tical casts doubt on the possibility that satavaptan has a direct
negative effect on the natural history of cirrhosis with ascites.
Figure 5 KaplaneMeier analysis of
all-cause mortality in study 3:
satavaptan versus placebo as single
therapy in the prevention of recurrent
ascites after large-volume paracentesis
(RR 0.95, 95% CI 0.60 to 1.51, p¼NS).
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The purpose of these three studies was not to assess the
effects of satavaptan on the management of hyponatraemia but
on the management of ascites. Therefore, the lack of efficacy of
satavaptan on the management of ascites does not negate the
results of numerous previous studies showing that vaptans are
efficacious in improving the serum sodium concentration in
patients with cirrhosis and dilutional (hypervolaemic) hypona-
traemia.7 8 11e13 15 Nevertheless, these results call for appropri-
ately designed studies to investigate the safety and efficacy of
vaptans in the long-term management of hyponatraemia in
cirrhosis.
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